Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O6LL
|
|||
| Drug Name |
PMID26560530-Compound-8
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
University of Texas
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H25N3O2S
|
|||
| Canonical SMILES |
CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCCCN
|
|||
| InChI |
1S/C17H25N3O2S/c1-20(2)16-10-6-9-15-14(16)8-7-11-17(15)23(21,22)19-13-5-3-4-12-18/h6-11,19H,3-5,12-13,18H2,1-2H3
|
|||
| InChIKey |
MLEBFEHOJICQQS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 10121-91-2
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:52007
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.